Can Voglibose be taken with metformin?

Can Voglibose be taken with metformin?

Conclusion: Therefore, it can be concluded that Metformin + Voglibose combination is very effective in reducing body weight, but further long term studies with large sample size are needed to assess the safety and efficacy of Metformin+ Voglibose combination in treatment of obesity in non-diabetic population.

Which anti diabetic drug can be taken in combination with metformin?

Metformin is available in combination with the following agents: rosiglitazone (Avandamet®), pioglitazone (Actoplus Met®), glipizide (Metaglip®), glibenclamide (Glucovance®), sitagliptin (Janumet®), and repaglinide (PrandiMet®).

What medication is combined with metformin?

Some “combination” pills have metformin with another medicine, including:

  • Glipizide and metformin (Metaglip)
  • Glyburide and metformin (Glucovance)
  • Pioglitazone and metformin (Actoplus Met)
  • Repaglinide and metformin (Prandimet)
  • Saxagliptin and metformin (Kombiglyze)
  • Sitagliptin and metformin (Janumet)

Which is better metformin or voglibose?

Metformin lowers the production and absorption of sugar in your body and allows better use of existing insulin. Voglibose inhibits the intestinal enzymes that cause breakdown of complex sugars into simple sugars such as glucose. This prevents blood glucose from rising very high after meals.

When do you take voglibose?

When should Voglibose be taken? Adults can take 0.2 mg of voglibose three times a day, right before each meal. Voglibose 0.2 mg or OD Tablets 0.2 mg will be taken orally three times daily, immediately before each meal.

Does voglibose contain metformin?

Metformin+Voglibose is used in the treatment of type 2 diabetes mellitus. Metformin + Voglibose is a combination of two antidiabetic medicines: Metformin and voglibose.

Which is better voglibose or metformin?

In conclusion, treatment with vogmet as a FDC of voglibose and metformin provided superior glycemic control for HbA1c, 2h-PPG, and FPG levels, greater in weight loss, and less glycemic variability than did metformin monotherapy in this 24-week study on Korean patients with T2DM.